[
    [
        {
            "time": "2018-01-02",
            "original_text": "The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst Blog",
                    "AbbVie",
                    "Oracle",
                    "GlaxoSmithKline",
                    "Kroger",
                    "Southern"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "technology",
                    "retail",
                    "utilities"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "medical stocks",
                    "outpaced"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-06-22",
            "original_text": "The Extreme Risks of Trading Your Own Retirement Assets - June 22, 2020",
            "features": {
                "keywords": [
                    "Extreme Risks",
                    "Trading",
                    "Retirement Assets"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "The Extreme Risks of Trading Your Own Retirement Assets - June 22, 2020",
                "Correlation": 1,
                "Sentiment": 4,
                "Importance": 3,
                "Impact": 1,
                "Duration": 2,
                "Entity_Density": 1,
                "Market_Scope": 2,
                "Time_Proximity": 1,
                "Headline_Structure": 6,
                "Source_Recency": 1
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity",
            "features": {
                "keywords": [
                    "FDA",
                    "Supplemental Biologics License Application",
                    "BOTOX",
                    "Pediatric Patients",
                    "Neurogenic Detrusor Overactivity"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]